579 related articles for article (PubMed ID: 10875855)
21. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
[TBL] [Abstract][Full Text] [Related]
22. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).
Lenton E; Soltan A; Hewitt J; Thomson A; Davies W; Ashraf N; Sharma V; Jenner L; Ledger W; McVeigh E
Hum Reprod; 2000 May; 15(5):1021-7. PubMed ID: 10783345
[TBL] [Abstract][Full Text] [Related]
23. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
24. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
25. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
Younis JS; Izhaki I; Ben-Ami M
Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
[TBL] [Abstract][Full Text] [Related]
26. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
27. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.
Kol S; Lightman A; Hillensjo T; Devroey P; Fauser B; Tarlatzis B; Mannaerts B; Itskovitz-Eldor J
Hum Reprod; 1999 Sep; 14(9):2242-4. PubMed ID: 10469687
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
Andersen AN; Witjes H; Gordon K; Mannaerts B;
Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
[TBL] [Abstract][Full Text] [Related]
29. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
[TBL] [Abstract][Full Text] [Related]
30. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
[TBL] [Abstract][Full Text] [Related]
32. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.
Hoomans EH; Mulder BB;
J Assist Reprod Genet; 2002 Oct; 19(10):470-6. PubMed ID: 12416651
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation.
Frattarelli JL; Hillensjö T; Broekmans FJ; Witjes H; Elbers J; Gordon K; Mannaerts B
Reprod Biol Endocrinol; 2013 Sep; 11():90. PubMed ID: 24028076
[TBL] [Abstract][Full Text] [Related]
34. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.
de Jong D; Macklon NS; Mannaerts BM; Coelingh Bennink HJ; Fauser BC
Hum Reprod; 1998 Mar; 13(3):573-5. PubMed ID: 9572414
[TBL] [Abstract][Full Text] [Related]
35. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
36. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
Out HJ; Lindenberg S; Mikkelsen AL; Eldar-Geva T; Healy DL; Leader A; Rodriguez-Escudero FJ; Garcia-Velasco JA; Pellicer A
Hum Reprod; 1999 Mar; 14(3):622-7. PubMed ID: 10221686
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
38. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
39. Addition of low-dose hCG to rFSH during ovarian stimulation for IVF/ICSI: is it beneficial?
Partsinevelos GA; Antonakopoulos N; Kallianidis K; Drakakis P; Anagnostou E; Bletsa R; Loutradis D
Clin Exp Obstet Gynecol; 2016; 43(6):818-825. PubMed ID: 29944230
[TBL] [Abstract][Full Text] [Related]
40. Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF.
Ravhon A; Lavery S; Michael S; Donaldson M; Margara R; Trew G; Winston R
Hum Reprod; 2000 Nov; 15(11):2297-301. PubMed ID: 11056122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
